Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 5,623 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 5,623 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total value of $1,147,822.99. Following the transaction, the chief executive officer directly owned 156,607 shares of the company’s stock, valued at $31,968,186.91. The trade was a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, March 2nd, Steven Leonard Chapman sold 3,950 shares of Natera stock. The stock was sold at an average price of $200.02, for a total value of $790,079.00.
• On Tuesday, February 3rd, Steven Leonard Chapman sold 4,725 shares of Natera stock. The shares were sold at an average price of $230.77, for a total value of $1,090,388.25.
• On Monday, February 2nd, Steven Leonard Chapman sold 85,299 shares of Natera stock. The stock was sold at an average price of $230.72, for a total transaction of $19,680,185.28.
• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $866,983.68.
• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total transaction of $881,499.84.

Natera Stock Down 1.2%

NTRA traded down $2.31 during trading hours on Thursday, reaching $194.30. 81,185 shares of the company’s stock traded hands, compared to its average volume of 1,163,021. The firm has a market capitalization of $27.54 billion, a PE ratio of -126.47 and a beta of 1.65. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The firm has a 50-day moving average price of $221.32 and a 200 day moving average price of $206.07.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. During the same period in the prior year, the firm earned ($0.41) earnings per share. Equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. JPMorgan Chase & Co. lifted its stake in Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after buying an additional 1,225,420 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Natera by 2.3% during the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after buying an additional 282,826 shares during the period. Wellington Management Group LLP boosted its position in Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares during the last quarter. State Street Corp grew its stake in Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after acquiring an additional 72,087 shares during the period. Finally, Franklin Resources Inc. raised its holdings in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on NTRA. TD Cowen reaffirmed a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Stephens raised their price objective on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Robert W. Baird boosted their target price on shares of Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a report on Friday, February 27th. UBS Group lifted their price target on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $253.47.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: MyOme announced the Zenith™ portfolio with Natera and launched long‑read methylation analysis at ACMG 2026 — a commercial/technology collaboration that could broaden Natera’s rare‑disease whole‑genome and epigenetic testing capabilities and help expand addressable market and clinical utility over time. MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
• Neutral Sentiment: Natera presented at the Leerink Global Healthcare Conference (transcript available). Management commentary in the presentation could provide useful color on product launches, adoption trends, and margin/reimbursement dynamics — read for guidance but the transcript itself is informational rather than catalytic. Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Significant insider selling disclosed: CEO Steven Leonard Chapman sold 5,623 shares (~$1.15M at ~$204.13) and reduced his stake ~3.47%; other insiders (CFO Michael Brophy, John Fesko, Solomon Moshkevich) also sold smaller positions. Multiple insider sales on the same date increase perceived near‑term selling risk and likely explain part of downward pressure on the shares. SEC Form 4 — CEO Sale

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.